Development of novel multipotent compounds modulating endocannabinoid and dopaminergic systems

Alessandro Grillo, Giulia Chemi, Simone Brogi, Margherita Brindisi, Nicola Relitti, Filomena Fezza, Domenico Fazio, Laura Castelletti, Elisabetta Perdona, Andrea Wong, Stefania Lamponi, Alessandra Pecorelli, Mascia Benedusi, Manuela Fantacci, Massimo Valoti, Giuseppe Valacchi, Fabrizio Micheli, Ettore Novellino, Giuseppe Campiani, Stefania ButiniMauro Maccarrone, Sandra Gemma

Research output: Contribution to journalArticle

Abstract

Polypharmacology approaches may help the discovery of pharmacological tools for the study or the potential treatment of complex and multifactorial diseases as well as for addictions and also smoke cessation. In this frame, following our interest in the development of molecules able to modulate either the endocannabinoid or the dopaminergic system, and given the multiple and reciprocal interconnections between them, we decided to merge the pharmacophoric elements of some of our early leads for identifying new molecules as tools able to modulate both systems. We herein describe the synthesis and biological characterization of compounds 5a-j inspired by the structure of our potent and selective fatty acid amide hydrolase (FAAH) inhibitors (3a-c) and ligands of dopamine D2 or D3 receptor subtypes (4a,b). Notably, the majority of the new molecules showed a nanomolar potency of interaction with the targets of interest. The drug-likeliness of the developed compounds (5a-j) was investigated in silico while hERG affinity, selectivity profile (for some proteins of the endocannabinoid system), cytotoxicity profiles (on fibroblast and astrocytes), and mutagenicity (Ames test) were experimentally determined. Metabolic studies also served to complement the preliminary drug-likeliness profiling for compounds 3a and 5c. Interestingly, after assessing the lack of toxicity for the neuroblastoma cell line (IMR 32), we demonstrated a potential anti-inflammatory profile for 3a and 5c in the same cell line.

Original languageEnglish
Article number111674
JournalEuropean Journal of Medicinal Chemistry
Volume183
DOIs
Publication statusPublished - Dec 1 2019

Fingerprint

Endocannabinoids
Polypharmacology
Dopamine D3 Receptors
Mutagenicity Tests
Cell Line
Molecules
Dopamine D2 Receptors
Neuroblastoma
Cells
Smoke
Astrocytes
Pharmaceutical Preparations
Computer Simulation
Anti-Inflammatory Agents
Fibroblasts
Pharmacology
Cytotoxicity
Ligands
Toxicity
Proteins

Keywords

  • Dopamine ligands
  • Dopamine receptor ligands
  • Endocannabinoid system
  • Enzyme inhibitors
  • Fatty acid amide hydrolase
  • Multitarget compounds
  • Polypharmacology
  • Selective inhibitors

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this

Development of novel multipotent compounds modulating endocannabinoid and dopaminergic systems. / Grillo, Alessandro; Chemi, Giulia; Brogi, Simone; Brindisi, Margherita; Relitti, Nicola; Fezza, Filomena; Fazio, Domenico; Castelletti, Laura; Perdona, Elisabetta; Wong, Andrea; Lamponi, Stefania; Pecorelli, Alessandra; Benedusi, Mascia; Fantacci, Manuela; Valoti, Massimo; Valacchi, Giuseppe; Micheli, Fabrizio; Novellino, Ettore; Campiani, Giuseppe; Butini, Stefania; Maccarrone, Mauro; Gemma, Sandra.

In: European Journal of Medicinal Chemistry, Vol. 183, 111674, 01.12.2019.

Research output: Contribution to journalArticle

Grillo, A, Chemi, G, Brogi, S, Brindisi, M, Relitti, N, Fezza, F, Fazio, D, Castelletti, L, Perdona, E, Wong, A, Lamponi, S, Pecorelli, A, Benedusi, M, Fantacci, M, Valoti, M, Valacchi, G, Micheli, F, Novellino, E, Campiani, G, Butini, S, Maccarrone, M & Gemma, S 2019, 'Development of novel multipotent compounds modulating endocannabinoid and dopaminergic systems', European Journal of Medicinal Chemistry, vol. 183, 111674. https://doi.org/10.1016/j.ejmech.2019.111674
Grillo, Alessandro ; Chemi, Giulia ; Brogi, Simone ; Brindisi, Margherita ; Relitti, Nicola ; Fezza, Filomena ; Fazio, Domenico ; Castelletti, Laura ; Perdona, Elisabetta ; Wong, Andrea ; Lamponi, Stefania ; Pecorelli, Alessandra ; Benedusi, Mascia ; Fantacci, Manuela ; Valoti, Massimo ; Valacchi, Giuseppe ; Micheli, Fabrizio ; Novellino, Ettore ; Campiani, Giuseppe ; Butini, Stefania ; Maccarrone, Mauro ; Gemma, Sandra. / Development of novel multipotent compounds modulating endocannabinoid and dopaminergic systems. In: European Journal of Medicinal Chemistry. 2019 ; Vol. 183.
@article{00e2ccc438444031acde347189e80b28,
title = "Development of novel multipotent compounds modulating endocannabinoid and dopaminergic systems",
abstract = "Polypharmacology approaches may help the discovery of pharmacological tools for the study or the potential treatment of complex and multifactorial diseases as well as for addictions and also smoke cessation. In this frame, following our interest in the development of molecules able to modulate either the endocannabinoid or the dopaminergic system, and given the multiple and reciprocal interconnections between them, we decided to merge the pharmacophoric elements of some of our early leads for identifying new molecules as tools able to modulate both systems. We herein describe the synthesis and biological characterization of compounds 5a-j inspired by the structure of our potent and selective fatty acid amide hydrolase (FAAH) inhibitors (3a-c) and ligands of dopamine D2 or D3 receptor subtypes (4a,b). Notably, the majority of the new molecules showed a nanomolar potency of interaction with the targets of interest. The drug-likeliness of the developed compounds (5a-j) was investigated in silico while hERG affinity, selectivity profile (for some proteins of the endocannabinoid system), cytotoxicity profiles (on fibroblast and astrocytes), and mutagenicity (Ames test) were experimentally determined. Metabolic studies also served to complement the preliminary drug-likeliness profiling for compounds 3a and 5c. Interestingly, after assessing the lack of toxicity for the neuroblastoma cell line (IMR 32), we demonstrated a potential anti-inflammatory profile for 3a and 5c in the same cell line.",
keywords = "Dopamine ligands, Dopamine receptor ligands, Endocannabinoid system, Enzyme inhibitors, Fatty acid amide hydrolase, Multitarget compounds, Polypharmacology, Selective inhibitors",
author = "Alessandro Grillo and Giulia Chemi and Simone Brogi and Margherita Brindisi and Nicola Relitti and Filomena Fezza and Domenico Fazio and Laura Castelletti and Elisabetta Perdona and Andrea Wong and Stefania Lamponi and Alessandra Pecorelli and Mascia Benedusi and Manuela Fantacci and Massimo Valoti and Giuseppe Valacchi and Fabrizio Micheli and Ettore Novellino and Giuseppe Campiani and Stefania Butini and Mauro Maccarrone and Sandra Gemma",
year = "2019",
month = "12",
day = "1",
doi = "10.1016/j.ejmech.2019.111674",
language = "English",
volume = "183",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - Development of novel multipotent compounds modulating endocannabinoid and dopaminergic systems

AU - Grillo, Alessandro

AU - Chemi, Giulia

AU - Brogi, Simone

AU - Brindisi, Margherita

AU - Relitti, Nicola

AU - Fezza, Filomena

AU - Fazio, Domenico

AU - Castelletti, Laura

AU - Perdona, Elisabetta

AU - Wong, Andrea

AU - Lamponi, Stefania

AU - Pecorelli, Alessandra

AU - Benedusi, Mascia

AU - Fantacci, Manuela

AU - Valoti, Massimo

AU - Valacchi, Giuseppe

AU - Micheli, Fabrizio

AU - Novellino, Ettore

AU - Campiani, Giuseppe

AU - Butini, Stefania

AU - Maccarrone, Mauro

AU - Gemma, Sandra

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Polypharmacology approaches may help the discovery of pharmacological tools for the study or the potential treatment of complex and multifactorial diseases as well as for addictions and also smoke cessation. In this frame, following our interest in the development of molecules able to modulate either the endocannabinoid or the dopaminergic system, and given the multiple and reciprocal interconnections between them, we decided to merge the pharmacophoric elements of some of our early leads for identifying new molecules as tools able to modulate both systems. We herein describe the synthesis and biological characterization of compounds 5a-j inspired by the structure of our potent and selective fatty acid amide hydrolase (FAAH) inhibitors (3a-c) and ligands of dopamine D2 or D3 receptor subtypes (4a,b). Notably, the majority of the new molecules showed a nanomolar potency of interaction with the targets of interest. The drug-likeliness of the developed compounds (5a-j) was investigated in silico while hERG affinity, selectivity profile (for some proteins of the endocannabinoid system), cytotoxicity profiles (on fibroblast and astrocytes), and mutagenicity (Ames test) were experimentally determined. Metabolic studies also served to complement the preliminary drug-likeliness profiling for compounds 3a and 5c. Interestingly, after assessing the lack of toxicity for the neuroblastoma cell line (IMR 32), we demonstrated a potential anti-inflammatory profile for 3a and 5c in the same cell line.

AB - Polypharmacology approaches may help the discovery of pharmacological tools for the study or the potential treatment of complex and multifactorial diseases as well as for addictions and also smoke cessation. In this frame, following our interest in the development of molecules able to modulate either the endocannabinoid or the dopaminergic system, and given the multiple and reciprocal interconnections between them, we decided to merge the pharmacophoric elements of some of our early leads for identifying new molecules as tools able to modulate both systems. We herein describe the synthesis and biological characterization of compounds 5a-j inspired by the structure of our potent and selective fatty acid amide hydrolase (FAAH) inhibitors (3a-c) and ligands of dopamine D2 or D3 receptor subtypes (4a,b). Notably, the majority of the new molecules showed a nanomolar potency of interaction with the targets of interest. The drug-likeliness of the developed compounds (5a-j) was investigated in silico while hERG affinity, selectivity profile (for some proteins of the endocannabinoid system), cytotoxicity profiles (on fibroblast and astrocytes), and mutagenicity (Ames test) were experimentally determined. Metabolic studies also served to complement the preliminary drug-likeliness profiling for compounds 3a and 5c. Interestingly, after assessing the lack of toxicity for the neuroblastoma cell line (IMR 32), we demonstrated a potential anti-inflammatory profile for 3a and 5c in the same cell line.

KW - Dopamine ligands

KW - Dopamine receptor ligands

KW - Endocannabinoid system

KW - Enzyme inhibitors

KW - Fatty acid amide hydrolase

KW - Multitarget compounds

KW - Polypharmacology

KW - Selective inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85071982708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071982708&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2019.111674

DO - 10.1016/j.ejmech.2019.111674

M3 - Article

AN - SCOPUS:85071982708

VL - 183

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

M1 - 111674

ER -